
There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.

Acceptance is greater in oncology than in other specialties.

ICER’s first scorecard of the barriers to fair access to medications found, of the policies that could be reviewed, most were structured to support fair access to medications.